The United States currently commands the largest share of the vascular dementia landscape, accounting for approximately 70% of the total 1.3 billion USD market value recorded in 2025. Despite this significant patient burden, there are currently no pharmacological therapies specifically indicated for the condition, forcing reliance on off-label treatments like antihypertensives and cholinesterase inhibitors to manage symptoms and vascular risk factors.

Optimism for a shift in the treatment paradigm rests on a maturing clinical pipeline. Companies including Resverlogix, Charsire Biotechnology, ProNeurogen, and Bausch Health are advancing candidates that target neurovascular dysfunction and inflammation. Among these, Resverlogix’s Apabetalone—a selective BET protein inhibitor—is anticipated to see moderate uptake following a projected 2032 launch. Other notable candidates in clinical trials include BAC, PNA1, and Rifaximin SSD. These emerging therapies aim to move beyond symptom management toward disease-modifying mechanisms, potentially transforming care for patients facing cognitive decline linked to vascular pathology.